ReviewNeuro-oncology advances2020
Abdominal neoplastic manifestations of neurofibromatosis type 1.
Review in Neuro-oncology advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Autonomic nervous system and gastrointestinal manifestations with an emphasis on gastric dysfunction.Autonomic neuroscience : basic & clinical · 2026Review
- Sporadic abdominopelvic neurofibroma presenting with genitourinary symptoms: A case report.Urology case reports · 2026Article
- An unexpected challenge: intra-abdominal neurofibromatosis during biliary reconstruction: a case report.Annals of medicine and surgery (2012) · 2026Article
- Type I neurofibromatosis with a solid pseudopapillary neoplasm of the pancreas: a case report and literature review.Discover oncology · 2026Article
- Isolated Anterior Mesenteric Neurofibroma: A Rare Manifestation of Neurofibromatosis Type 1.Cureus · 2026Article
- Frequency and Characteristics of Gastrointestinal Diseases in Patients With Neurofibromatosis.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- The role of multimodality imaging in diffuse pelvicoabdominal plexiform neurofibroma: A rare case report.Radiology case reports · 2024Article
- Vascular complications during appendectomy: severe adhesion of the appendix to the right iliac artery: a case report.Journal of medical case reports · 2024Article
- Neurofibromatosis Type 1: Optimizing Management with a Multidisciplinary Approach.Journal of multidisciplinary healthcare · 2024Review
- MULTIPLE NEUROENDOCRINE NEOPLASIA IN A PATIENT WITH TYPE I NEUROFIBROMATOSIS (NF1): REPORT OF A NEW MUTATION (NF1, EXONS 2-30 DELETION) AND LITERATURE REVIEW.Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2023Review
- Gastric Malignant Peripheral Nerve Sheath Tumor in Type 1 Neurofibromatosis.The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2022Article
- Pediatric adrenocortical carcinoma.Frontiers in endocrinology · 2022Review
- Case report: First case of undifferentiated embryonal sarcoma of the liver in a child with neurofibromatosis type 1, treated by hepatic chemoperfusion with transcatheter arterial chemoembolization.Frontiers in oncology · 2022Article
- Article
- Gastrointestinal motility disorders in neurologic disease.The Journal of clinical investigation · 2021Review
- Adrenocortical carcinoma in a patient with neurofibromatosis type 1: A case report.Caspian journal of internal medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurofibromatosis type 1 (NF1) is an autosomal dominant hereditary tumor syndrome, with a wide clinicopathologic spectrum. It is defined by characteristic central nervous system, cutaneous and osseous manifestations, and by mutations in the NF1 gene, which is involved in proliferation via p21, RAS, and MAP kinase pathways. Up to 25% of NF1 patients develop intra-abdominal neoplastic manifestations including neurogenic (commonly plexiform neurofibromas and malignant peripheral nerve sheath tumors), interstitial cells of Cajal (hyperplasia, gastrointestinal stromal tumors), neuroendocrine, and embryonal tumors (rhabdomyosarcoma). Nonspecific symptoms, multifocal disease, or coexistence of 2 or more tumor types make patients challenging to diagnose and manage. Screening for intra-abdominal tumors in NF1 patients remains controversial, and currently no guidelines are established. Management decisions are complex and often informed by single-center experiences or case studies in the literature, though the field is rapidly evolving. Thus, NF1 patients should be followed in specialist centers familiar with their wide spectrum of pathology and with multidisciplinary care including specialized pathology and radiology. This review will (1) provide a contemporaneous synthesis of the literature and our multi-institutional clinical experiences with intra-abdominal neoplasms in NF1 patients, (2) present a classification framework for this heterogeneous group of disorders, and (3) outline approaches to screening, surveillance, diagnosis, and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.